Clene Nanomedicine has become the first clinical trial sponsor to produce data outputs with InStat, the automated biostatistics platform run by the contract research organisation Veristat, according to a report published on 18 November 20261. Veristat says the program cut the time needed to deliver biostatistical outputs for Clene's drug application by 80%1.
What the platform did
Clene used InStat to produce the tables, listings and figures for its biomarker analysis. The work took one week, against six weeks by the usual route1. The figures relate to CNM-Au8, Clene's oral gold nanocrystal suspension for amyotrophic lateral sclerosis (ALS), which the Salt Lake City company submitted to the FDA for approval nearly a year ago1. That submission rested on phase 2 data from 2023 in which the drug improved survival for ALS patients even though it missed its primary endpoint1.
Veristat launched InStat in May. It describes the program as a zero-code, fully automated biostatistics service meant to reduce manual effort, with each output backed by validated statistical engines and checked by an expert biostatistician1. The stated aim is a shorter path to approval1.
The design choice matters as much as the speed claim. Kyle McBride, Veristat's vice president for AI and innovation, said the company had "intentionally put AI where it adds speed, not where it adds risk"1. In his account the AI helps biostatisticians turn what they intend to analyse into exact specifications, and the downstream statistics then run on established engines1. "Once that's right, everything downstream is trustworthy," McBride said1.
What it means for the market
For sponsors, the claim is about time to filing: Veristat built the program to speed up the route to approval, and a cut from six weeks to one on a piece of submission work is the evidence it offers1. Veristat is positioning the product as a way to change how this work is done, with McBride saying the company is "re-engineering how complex biostatistical work gets done in clinical research"1.
For other contract research organisations, the pitch sets a benchmark that buyers can now ask about: AI confined to specification, with validated engines and human review behind every output1.
What the source does not give is any independent check. The 80% figure and the one-week turnaround come from the company, and they describe a single sponsor and a single biomarker analysis1. The source gives no price, no wider customer list and no word on how the FDA has treated outputs produced this way1.
The open question for buyers is whether the same gain holds beyond one biomarker analysis for one sponsor, which is the only use the source describes1.
Sources
- Clene Nanomedicine uses CRO Veristat’s biostatistics platform for FDA submission (opens in a new tab)Fierce Biotech · fiercebiotech.com
This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.